Last Updated : June 8, 2017
Details
FilesGeneric Name:
Evolocumab
Project Status:
Complete
Therapeutic Area:
Primary hyperlipidemia and mixed dyslipidemia
Manufacturer:
Amgen Canada Inc.
Brand Name:
Repatha
Project Line:
Reimbursement Review
Project Number:
SR0515-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Resubmission
Indications:
Primary hyperlipidemia and mixed dyslipidemia
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : June 8, 2017